Skip to main content
Top
Published in: Hepatology International 2/2022

01-04-2022 | Fatty Liver | Original Article

Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease

Authors: Maki Morinaga, Kazuyoshi Kon, Akira Uchiyama, Hiroo Fukada, Kyoko Fukuhara, Reiko Yaginuma, Eisuke Nakadera, Shunhei Yamashina, Kenichi Ikejima

Published in: Hepatology International | Issue 2/2022

Login to get access

Abstract

Background

The prevalence of nonalcoholic fatty liver disease (NAFLD) and alcohol-associated/related liver disease (ALD) with metabolic syndrome is increasing globally. Metabolic syndrome and excessive alcohol consumption synergically exacerbate liver pathologies; therefore, drinking-specific serum markers unaffected by liver injury or metabolic syndrome are essential for assessing alcohol consumption. We evaluated the ratio of carbohydrate-deficient transferrin to total transferrin (%CDT) in patients with fatty liver disease, particularly focusing on its correlation with metabolic factors (UMIN000033550).

Methods

A total of 120 patients with fatty liver disease, including ALD and NAFLD, were screened for alcohol misuse using the Alcohol Use Disorders Identification Test. Associations of metabolic syndrome-related factors and hepatic steatosis/liver stiffness with drinking markers, such as %CDT, gamma-glutamyl transferase (GGT), and mean corpuscular volume (MCV), were assessed using multiple linear regression analyses.

Results

%CDT significantly increased with 3–4 drinks/day. The optimal cutoff value for identifying non- to light drinkers was 1.78% (sensitivity, 71.8%; specificity, 83.7%; and area under the receiver operating characteristic curve [AUROC], 0.851), which was significantly higher than that for GGT. The cutoff value for identifying heavy drinkers was 2.08% (sensitivity, 65.5%; specificity, 86.8%; and AUROC, 0.815). Multiple regression analysis revealed that this proportion was negatively correlated with body mass index, whereas GGT and MCV were influenced by multiple factors involved in liver injury and dyslipidemia.

Conclusions

%CDT showed a strong correlation with alcohol consumption, independent of liver damage, steatosis/stiffness, or metabolic syndrome-related factors, indicating that it is a useful drinking marker for the accurate diagnosis of NAFLD and ALD.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. The Lancet. 2019;393(10190):2493–2502CrossRef Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. The Lancet. 2019;393(10190):2493–2502CrossRef
3.
go back to reference Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54(4):367–376CrossRefPubMed Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. J Gastroenterol. 2019;54(4):367–376CrossRefPubMed
4.
go back to reference Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904CrossRefPubMed Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904CrossRefPubMed
5.
go back to reference Suzuki M, Kon K, Ikejima K, Arai K, Uchiyama A, Aoyama T, et al. The chemical chaperone 4-phenylbutyric acid prevents alcohol-induced liver injury in obese KK-A(y) mice. Alcohol Clin Exp Res. 2019;43(4):617–627CrossRefPubMed Suzuki M, Kon K, Ikejima K, Arai K, Uchiyama A, Aoyama T, et al. The chemical chaperone 4-phenylbutyric acid prevents alcohol-induced liver injury in obese KK-A(y) mice. Alcohol Clin Exp Res. 2019;43(4):617–627CrossRefPubMed
6.
go back to reference Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung H-S, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69(1):64–75CrossRefPubMed Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung H-S, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69(1):64–75CrossRefPubMed
7.
go back to reference Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59(10):1410–1415CrossRefPubMed Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59(10):1410–1415CrossRefPubMed
8.
go back to reference Mahli A, Hellerbrand C. Alcohol and obesity: a dangerous association for fatty liver disease. Dig Dis. 2016;34(Suppl 1):32–39CrossRefPubMed Mahli A, Hellerbrand C. Alcohol and obesity: a dangerous association for fatty liver disease. Dig Dis. 2016;34(Suppl 1):32–39CrossRefPubMed
9.
go back to reference Ikejima K, Kon K, Yamashina S. Nonalcoholic fatty liver disease and alcohol-related liver disease: from clinical aspects to pathophysiological insights. Clin Mol Hepatol. 2020;26(4):728–735CrossRefPubMedPubMedCentral Ikejima K, Kon K, Yamashina S. Nonalcoholic fatty liver disease and alcohol-related liver disease: from clinical aspects to pathophysiological insights. Clin Mol Hepatol. 2020;26(4):728–735CrossRefPubMedPubMedCentral
10.
go back to reference Bergstrom JP, Helander A. Clinical characteristics of carbohydrate-deficient transferrin (%disialotransferrin) measured by HPLC: sensitivity, specificity, gender effects, and relationship with other alcohol biomarkers. Alcohol Alcohol. 2008;43(4):436–441CrossRefPubMed Bergstrom JP, Helander A. Clinical characteristics of carbohydrate-deficient transferrin (%disialotransferrin) measured by HPLC: sensitivity, specificity, gender effects, and relationship with other alcohol biomarkers. Alcohol Alcohol. 2008;43(4):436–441CrossRefPubMed
11.
go back to reference Helander A, Husa A, Jeppsson JO. Improved HPLC method for carbohydrate-deficient transferrin in serum. Clin Chem. 2003;49(11):1881–1890CrossRefPubMed Helander A, Husa A, Jeppsson JO. Improved HPLC method for carbohydrate-deficient transferrin in serum. Clin Chem. 2003;49(11):1881–1890CrossRefPubMed
12.
go back to reference Tavakoli HR, Hull M, Michael OL. Review of current clinical biomarkers for the detection of alcohol dependence. Innov Clin Neurosci. 2011;8(3):26–33PubMedPubMedCentral Tavakoli HR, Hull M, Michael OL. Review of current clinical biomarkers for the detection of alcohol dependence. Innov Clin Neurosci. 2011;8(3):26–33PubMedPubMedCentral
13.
go back to reference Ohtsuka T, Tsutsumi M, Fukumura A, Tsuchishima M, Takase S. Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. Alcohol Clin Exp Res. 2005;29(12 Suppl):236S-S239CrossRefPubMed Ohtsuka T, Tsutsumi M, Fukumura A, Tsuchishima M, Takase S. Use of serum carbohydrate-deficient transferrin values to exclude alcoholic hepatitis from non-alcoholic steatohepatitis: a pilot study. Alcohol Clin Exp Res. 2005;29(12 Suppl):236S-S239CrossRefPubMed
14.
go back to reference Wang J, Li P, Jiang Z, Yang Q, Mi Y, Liu Y, et al. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD. Korean J Intern Med. 2016;31(3):479–487CrossRefPubMedPubMedCentral Wang J, Li P, Jiang Z, Yang Q, Mi Y, Liu Y, et al. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD. Korean J Intern Med. 2016;31(3):479–487CrossRefPubMedPubMedCentral
15.
go back to reference Sakutata H, Suzuki T, Yasuda H, Ito T. Beverage-specific effects of ethanol consumption on its biological markers. Clin Chem Lab Med. 2008;46(5):699–702PubMed Sakutata H, Suzuki T, Yasuda H, Ito T. Beverage-specific effects of ethanol consumption on its biological markers. Clin Chem Lab Med. 2008;46(5):699–702PubMed
16.
go back to reference Delanghe JR, Helander A, Wielders JP, Pekelharing JM, Roth HJ, Schellenberg F, et al. Development and multicenter evaluation of the N latex CDT direct immunonephelometric assay for serum carbohydrate-deficient transferrin. Clin Chem. 2007;53(6):1115–1121CrossRefPubMed Delanghe JR, Helander A, Wielders JP, Pekelharing JM, Roth HJ, Schellenberg F, et al. Development and multicenter evaluation of the N latex CDT direct immunonephelometric assay for serum carbohydrate-deficient transferrin. Clin Chem. 2007;53(6):1115–1121CrossRefPubMed
17.
go back to reference Szegedi A, Muller MJ, Himmerich H, Anghelescu I, Wetzel H. Carbohydrate-deficient transferrin (CDT) and HDL cholesterol (HDL) are highly correlated in male alcohol dependent patients. Alcohol Clin Exp Res. 2000;24(4):497–500CrossRefPubMed Szegedi A, Muller MJ, Himmerich H, Anghelescu I, Wetzel H. Carbohydrate-deficient transferrin (CDT) and HDL cholesterol (HDL) are highly correlated in male alcohol dependent patients. Alcohol Clin Exp Res. 2000;24(4):497–500CrossRefPubMed
18.
go back to reference Hock B, Schwarz M, Domke I, Grunert VP, Wuertemberger M, Schiemann U, et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction. 2005;100(10):1477–1486CrossRefPubMed Hock B, Schwarz M, Domke I, Grunert VP, Wuertemberger M, Schiemann U, et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction. 2005;100(10):1477–1486CrossRefPubMed
19.
go back to reference Suzuki T, Eguchi A, Shigefuku R, Nagao S, Morikawa M, Sugimoto K, et al. Accuracy of carbohydrate-deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism. Hepatol Res. 2021;2021:5 Suzuki T, Eguchi A, Shigefuku R, Nagao S, Morikawa M, Sugimoto K, et al. Accuracy of carbohydrate-deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism. Hepatol Res. 2021;2021:5
20.
go back to reference Hietala J, Koivisto H, Anttila P, Niemela O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol. 2006;41(5):528–533CrossRefPubMed Hietala J, Koivisto H, Anttila P, Niemela O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol. 2006;41(5):528–533CrossRefPubMed
21.
go back to reference Liang SS, He Y, Huang ZG, Jia CY, Gan W. Evaluation of the diagnostic utility of carbohydrate-deficient transferrin in chronic alcoholism: Results from Southwest China. Med (Baltim). 2021;100(4):e24467CrossRef Liang SS, He Y, Huang ZG, Jia CY, Gan W. Evaluation of the diagnostic utility of carbohydrate-deficient transferrin in chronic alcoholism: Results from Southwest China. Med (Baltim). 2021;100(4):e24467CrossRef
22.
go back to reference Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson L, et al. Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. BMC Gastroenterol. 2014;14:97CrossRefPubMedPubMedCentral Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson L, et al. Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers. BMC Gastroenterol. 2014;14:97CrossRefPubMedPubMedCentral
23.
go back to reference Schellenberg F, Schwan R, Mennetrey L, Loiseaux MN, Pages JC, Reynaud M. Dose-effect relation between daily ethanol intake in the range 0–70 grams and %CDT value: validation of a cut-off value. Alcohol Alcohol. 2005;40(6):531–534CrossRefPubMed Schellenberg F, Schwan R, Mennetrey L, Loiseaux MN, Pages JC, Reynaud M. Dose-effect relation between daily ethanol intake in the range 0–70 grams and %CDT value: validation of a cut-off value. Alcohol Alcohol. 2005;40(6):531–534CrossRefPubMed
24.
go back to reference Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66(3):610–618CrossRefPubMed Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017;66(3):610–618CrossRefPubMed
25.
go back to reference Whitfield JB, Dy V, Madden PA, Heath AC, Martin NG, Montgomery GW. Measuring carbohydrate-deficient transferrin by direct immunoassay: factors affecting diagnostic sensitivity for excessive alcohol intake. Clin Chem. 2008;54(7):1158–1165CrossRefPubMed Whitfield JB, Dy V, Madden PA, Heath AC, Martin NG, Montgomery GW. Measuring carbohydrate-deficient transferrin by direct immunoassay: factors affecting diagnostic sensitivity for excessive alcohol intake. Clin Chem. 2008;54(7):1158–1165CrossRefPubMed
26.
go back to reference Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson LA, et al. BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin. Alcohol Clin Exp Res. 2013;37(10):1771–1778PubMed Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson LA, et al. BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin. Alcohol Clin Exp Res. 2013;37(10):1771–1778PubMed
27.
go back to reference Kalapatapu RK, Chambers R. Novel objective biomarkers of alcohol use: potential diagnostic and treatment management tools in dual diagnosis care. J Dual Diagn. 2009;5(1):57–82CrossRefPubMedPubMedCentral Kalapatapu RK, Chambers R. Novel objective biomarkers of alcohol use: potential diagnostic and treatment management tools in dual diagnosis care. J Dual Diagn. 2009;5(1):57–82CrossRefPubMedPubMedCentral
28.
go back to reference Hultberg B, Isaksson A, Agardh E, Agardh CD. Plasma beta-hexosaminidase isoenzymes A and B exhibit different relations to blood glucose levels in a population of Type 1 diabetic patients. Scand J Clin Lab Invest. 1995;55(8):723–728CrossRefPubMed Hultberg B, Isaksson A, Agardh E, Agardh CD. Plasma beta-hexosaminidase isoenzymes A and B exhibit different relations to blood glucose levels in a population of Type 1 diabetic patients. Scand J Clin Lab Invest. 1995;55(8):723–728CrossRefPubMed
29.
go back to reference Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209CrossRefPubMed Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209CrossRefPubMed
Metadata
Title
Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease
Authors
Maki Morinaga
Kazuyoshi Kon
Akira Uchiyama
Hiroo Fukada
Kyoko Fukuhara
Reiko Yaginuma
Eisuke Nakadera
Shunhei Yamashina
Kenichi Ikejima
Publication date
01-04-2022
Publisher
Springer India
Published in
Hepatology International / Issue 2/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-022-10298-8

Other articles of this Issue 2/2022

Hepatology International 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.